Combating the growing problem of methicillin-resistant Staphylococcus aureus: Do the newer antibiotics represent a better alternative to vancomycin?

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 3, 2007, Pages 333-335

  Chambers, Henry F ^a   Hegde, Sharath S ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; GENTAMICIN; LINEZOLID; METICILLIN; NEW DRUG; OXACILLIN; PENICILLIN G; TIGECYCLINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; UNCLASSIFIED DRUG; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BONE MARROW TOXICITY; CLINICAL TRIAL; COMMUNICABLE DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENTEROCOCCUS; ERADICATION THERAPY; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUSCLE DISEASE; NAUSEA; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; RISK ASSESSMENT; RISK FACTOR; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; PENICILLIN RESISTANCE; REVIEW; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; METHICILLIN RESISTANCE; MINOCYCLINE; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 34447254269     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.3.333     Document Type: Editorial

References (27)

1. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40(4), 562-573 (2005).
2. Chambers HF. Community-associated MRSA - resistance and virulence converge. N. Engl. J. Med. 352(14), 1485-1487 (2005).
3. Styers D, Sheehan DJ, Hogan P, Sahm DF. laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
4. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
5. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144(5), 309-317 (2006).
6. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin. Infect. Dis. 39(7), 971-979 (2004).
7. Moellering RC Jr. The management of infections due to drug-resistant Gram-positive bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 24(12), 777-779 (2005).
8. Ziglam HM, Finch RG. Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clin. Microbiol. Infect. 7(Suppl. 4), 53-65 (2001).
9. Murray BE. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342(10), 710-721 (2000).
10. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1), S40-S50 (2006).
11. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38(12), 1700-1705 (2004).
12. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6), 2398-2402 (2004).
13. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27(2), 227-249 (2007).
14. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36(4), 473-481 (2003).
15. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev. Anti Infect. Ther. 2(1), 51-59 (2004).
16. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44(12), 3408-3413 (2000).
17. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49(6), 2260-2266 (2005).
18. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25(3), 980-992 (2003).
19. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32(3), 402-412 (2001).
20. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124(5), 1789-1797 (2003).
21. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207-208 (2001).
22. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am. J. Med. Sci. 330(2), 102-104 (2005).
23. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41(Suppl. 5), S303-S314 (2005).
24. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5), S341-S353 (2005).
25. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38(7), 994-1000 (2004).
26. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38(12), 1673-1681 (2004).
27. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355(7), 653-665 (2006).